Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Huzhou Central Hospital | OTHER |
| Ningbo Medical Center Lihuili Hospital | OTHER_GOV |
| Hangzhou Hospital of Traditional Chinese Medicine | OTHER |
| The first people Hospital of Linhai |
Not provided
Not provided
Not provided
Not provided
Multicenter, double-blind, and randomized controlled trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | Transcetaneous Electrical Stimulation |
|
| Group B | Placebo Comparator | Fake Stimulus Group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trail of Ultral-distal Transcutaneous Electrical Nerve Stimulation | Device | When subjects report experiencing or impending headache episodes, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) therapy in the treatment area. Prior to activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Subsequently, activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. A safety follow-up (telephone consultation or online questionnaire) should be completed one week after the treatment session. |
| Measure | Description | Time Frame |
|---|---|---|
| Reduce the intensity of migraine | After treatment, participants rated their headache intensity as 0 (no pain =0 points, mild =1 point, moderate =2 points, severe =3 points). | Baseline and 2 hours post-treatment |
| the pre-selected accompanying symptoms | Participants no longer experienced the pre-selected accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) after 2 hours of treatment. | Baseline and 2 hours post-treatment |
| Measure | Description | Time Frame |
|---|---|---|
| pain relief | Pain relief measured by Visual Analogue Scale (VAS):Number of participants transitioning from moderate to mild pain at 2 hours post-treatment. | Baseline and 2 hours post-treatment |
| returned to normal function |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Electrical stimulator | Hangzhou | Zhejiang | 311100 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33302882 | Result | Moisset X, Pereira B, Ciampi de Andrade D, Fontaine D, Lanteri-Minet M, Mawet J. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020 Dec 10;21(1):142. doi: 10.1186/s10194-020-01204-4. | |
| 31578882 | Result |
Not provided
Not provided
It is necessary to explore how personal information is protected.
Not provided
Not provided
Not provided
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Fake Stimulus | Device | When subjects experience or anticipate headache onset, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) in a non-treatment area. Before activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Then activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. Complete a safety follow-up one week after the same-day treatment (via telephone consultation or online questionnaire). |
|
Number of participants who resumed normal daily activities (e.g., ability to ambulate freely or return to work/school) by 2 hours post-treatment.
| Baseline and 2 hours post-treatment |
| Use of acute treatment drugs | Use of acute treatment drugs within 24 hours of treatment | Baseline and 24 hours post-treatment |
| recurrence of migraine | No recurrence of migraine attack occurred within 2-24 hours after treatment | Baseline and 2-24 hours post-treatment |
| recurrence of migraine2 | No recurrence of migraine attack occurred within 2-48 hours after treatment | Baseline and 2-48 hours post-treatment |
| pain-free status | Participants achieved pain-free status (VAS score 0) at 15,30,45,60, and 90 minutes post-treatment, having progressed from moderate to severe pain. | Baseline and 15,30,45,60, and 90 minutes post-treatment |
| symptoms free | Participants' accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) did not reappear at 15,30,45,60, and 90 minutes after treatment | Baseline and 15,30,45,60, and 90 minutes post-treatment |
| Weatherall MW, Nandi D. Percutaneous electrical nerve stimulation (PENS) therapy for refractory primary headache disorders: a pilot study. Br J Neurosurg. 2019 Dec;33(6):608-612. doi: 10.1080/02688697.2019.1671951. Epub 2019 Oct 3. |
| 33773613 | Result | Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-1495. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25. |
| 21886108 | Result | Tufail Y, Yoshihiro A, Pati S, Li MM, Tyler WJ. Ultrasonic neuromodulation by brain stimulation with transcranial ultrasound. Nat Protoc. 2011 Sep 1;6(9):1453-70. doi: 10.1038/nprot.2011.371. |
| 36709924 | Result | Tang Z, Ma Q, Li Q, Hu J, Wang C, Jiao W, Song X, Wu Y, Du L, Jin Y. Advances in applications of head mounted devices (HMDs): Physical techniques for drug delivery and neuromodulation. J Control Release. 2023 Feb;354:810-820. doi: 10.1016/j.jconrel.2023.01.061. Epub 2023 Jan 30. |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided